ATE360693T1 - Baff rezeptor (bcma), ein immunoregulatorisches mittel - Google Patents

Baff rezeptor (bcma), ein immunoregulatorisches mittel

Info

Publication number
ATE360693T1
ATE360693T1 AT00957502T AT00957502T ATE360693T1 AT E360693 T1 ATE360693 T1 AT E360693T1 AT 00957502 T AT00957502 T AT 00957502T AT 00957502 T AT00957502 T AT 00957502T AT E360693 T1 ATE360693 T1 AT E360693T1
Authority
AT
Austria
Prior art keywords
bcma
baff receptor
immunoregulatory agent
baff
receptor
Prior art date
Application number
AT00957502T
Other languages
English (en)
Inventor
Fabienne Mackay
Jeffrey Browning
Christine Ambrose
Jurg Tschopp
Pascal Schneider
Jeffrey Thompson
Original Assignee
Biogen Idec Inc
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27386828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE360693(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc, Apotech R & D Sa filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE360693T1 publication Critical patent/ATE360693T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
AT00957502T 1999-08-17 2000-08-16 Baff rezeptor (bcma), ein immunoregulatorisches mittel ATE360693T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14937899P 1999-08-17 1999-08-17
US18168400P 2000-02-11 2000-02-11
US18353600P 2000-02-18 2000-02-18

Publications (1)

Publication Number Publication Date
ATE360693T1 true ATE360693T1 (de) 2007-05-15

Family

ID=27386828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957502T ATE360693T1 (de) 1999-08-17 2000-08-16 Baff rezeptor (bcma), ein immunoregulatorisches mittel

Country Status (29)

Country Link
US (7) US7691804B2 (de)
EP (3) EP1806143B1 (de)
JP (4) JP4787439B2 (de)
KR (2) KR20090016772A (de)
CN (1) CN100447244C (de)
AT (1) ATE360693T1 (de)
AU (1) AU780240B2 (de)
BG (1) BG106519A (de)
BR (2) BR0013391A (de)
CA (1) CA2383154C (de)
CZ (1) CZ300364B6 (de)
DE (1) DE60034579T3 (de)
DK (1) DK1210425T4 (de)
EA (1) EA004635B1 (de)
EE (1) EE05673B1 (de)
GE (1) GEP20053685B (de)
HK (1) HK1043608B (de)
HU (3) HU227947B1 (de)
IL (3) IL148089A0 (de)
IS (1) IS2955B (de)
MX (1) MXPA02001665A (de)
NO (2) NO331410B1 (de)
NZ (1) NZ517782A (de)
PL (2) PL211786B1 (de)
RS (1) RS51157B (de)
SK (2) SK288287B6 (de)
TR (1) TR200201063T2 (de)
UA (1) UA75049C2 (de)
WO (1) WO2001012812A2 (de)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
WO2002094852A2 (en) 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
EP1806143B1 (de) * 1999-08-17 2016-06-15 Biogen MA Inc. BAFF-Rezeptor (BCMA), ein immunregulatorischer Wirkstoff
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
ATE511857T1 (de) * 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
WO2001087979A2 (en) * 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR20120053525A (ko) * 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
DE10049010A1 (de) * 2000-10-04 2002-04-18 Boehringer Ingelheim Int Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
IL160127A0 (en) * 2001-08-03 2004-06-20 Genentech Inc Tacis and br3 polypeptides and uses thereof
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
CA2492447A1 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
EP1629001A2 (de) * 2003-06-05 2006-03-01 Genentech, Inc. Blys-antagonisten und deren verwendung
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
MXPA06004301A (es) 2003-10-20 2006-06-05 Biogen Idec Inc Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
CA2554526A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
US20080181886A1 (en) * 2004-11-04 2008-07-31 Genentech, Inc. Polypeptides That Bind Baff And/Or April
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
EP1855711B1 (de) * 2005-01-28 2009-06-17 Biogen Idec MA Inc. VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
EP1922080A2 (de) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) * 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
WO2010007082A1 (en) 2008-07-17 2010-01-21 Novartis Ag Compositions and methods of use for therapeutic antibodies
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010093993A2 (en) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
HRP20161194T1 (hr) 2009-03-10 2016-11-04 Biogen Ma Inc. Anti-bcma protutijela
EP3211094A3 (de) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Verfahren zur behandlung, diagnose und überwachung rheumatoider arthritis
CN101781680B (zh) * 2009-10-19 2012-05-09 南通大学附属医院 测定对人baff-r基因启动子活性影响因素的方法
WO2011108008A2 (en) * 2010-03-04 2011-09-09 Transgene Biotek Ltd. Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
FI3415531T3 (fi) * 2011-05-27 2023-09-07 Glaxo Group Ltd Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
SG11201404486QA (en) 2012-01-31 2014-11-27 Genentech Inc Anti-ig-e m1' antibodies and methods using same
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
CN106459990B (zh) 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
EP3193915A1 (de) 2014-07-21 2017-07-26 Novartis AG Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
SMT202100221T1 (it) * 2014-12-05 2021-07-12 Memorial Sloan Kettering Cancer Center Anticorpi bersaglianti l'antigene di maturazione delle cellule e metodi d'uso
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
PT3283106T (pt) 2015-04-13 2022-02-02 Pfizer Anticorpos terapêuticos e as suas utilizações
KR102208443B1 (ko) 2015-04-13 2021-01-27 화이자 인코포레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3331913A1 (de) 2015-08-07 2018-06-13 Novartis AG Behandlung von krebs mithilfe von chimären cd3-rezeptor-proteinen
EP4458957A3 (de) 2015-11-23 2025-03-05 Novartis AG Optimierte lentivirale transfervektoren und verwendungen davon
RU2018127657A (ru) 2015-12-30 2020-01-31 Новартис Аг Виды терапии на основе иммуноэффекторных клеток с улучшенной эффективностью
JP7152309B2 (ja) 2016-02-17 2022-10-12 シージェン インコーポレイテッド 癌及び免疫学的障害を治療するためのｂｃｍａ抗生物質及びその使用
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
CN116041514A (zh) * 2016-06-06 2023-05-02 希望之城 Baff-r抗体及其用途
BR112018076767A2 (pt) 2016-06-21 2019-04-02 Teneobio, Inc. anticorpos de ligação a cd3
MX2019002967A (es) 2016-09-14 2019-07-04 Teneobio Inc Anticuerpos de union a cd3.
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
KR20250016462A (ko) 2016-12-21 2025-02-03 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
EP4043485A1 (de) 2017-01-26 2022-08-17 Novartis AG Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
EP3577134A1 (de) 2017-01-31 2019-12-11 Novartis AG Behandlung von krebs mit chimären t-zellrezeptorproteinen mit mehreren spezifitäten
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3615055A1 (de) 2017-04-28 2020-03-04 Novartis AG Zellen, die einen auf bcma abzielenden chimären antigenrezeptor exprimieren, und kombinationsbehandlung mit einem gamma-sekretase-inhibitor
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CA3062506A1 (en) 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3694997A4 (de) 2017-10-12 2021-06-30 Mcmaster University T-zellen-antigen-koppler mit y182t-mutation und verfahren und verwendungen davon
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
SG11202003501XA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
RU2020119365A (ru) 2017-11-15 2021-12-13 Новартис Аг Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
EP3737408A1 (de) 2018-01-08 2020-11-18 Novartis AG Immunstimulierende rnas zur kombination mit einer chimären antigen-rezeptor-therapie
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3746116A1 (de) 2018-01-31 2020-12-09 Novartis AG Kombinationstherapie unter verwendung eines chimären antigenrezeptors
EP3752203A1 (de) 2018-02-13 2020-12-23 Novartis AG Chimäre antigenrezeptortherapie in kombination mit il-15r und il15
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3784351A1 (de) 2018-04-27 2021-03-03 Novartis AG Car-t-zelltherapien mit erhöhter wirksamkeit
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
JP7542441B2 (ja) 2018-05-11 2024-08-30 クリスパー セラピューティクス アクチェンゲゼルシャフト 癌を治療するための方法及び組成物
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
MA69412B1 (fr) 2018-07-19 2025-12-31 Regeneron Pharmaceuticals, Inc. Récepteurs antigéniques chimériques présentant une spécificité pour bcma et leurs utilisations
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
EP3844265A2 (de) 2018-08-31 2021-07-07 Novartis AG Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
TW202538050A (zh) 2018-08-31 2025-10-01 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
MX2021012205A (es) 2019-04-05 2022-02-21 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma.
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
US20220249558A1 (en) 2019-04-30 2022-08-11 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
UY38748A (es) 2019-06-14 2021-01-29 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2021003432A1 (en) 2019-07-02 2021-01-07 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
BR112022010206A2 (pt) 2019-11-26 2022-11-29 Novartis Ag Receptores de antígeno quiméricos e usos dos mesmos
CN115052662A (zh) 2019-12-20 2022-09-13 诺华股份有限公司 抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CA3173737A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
KR20250007022A (ko) 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP4182003A1 (de) 2020-07-15 2023-05-24 Cerebral Therapeutics, Inc. Medizinische vorrichtung mit nicht gefiltertem csf-entnahmepfad
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20240294604A1 (en) * 2020-08-12 2024-09-05 The Board Of Trustees Of The Leland Stanford Junior University sBCMA Variants and FC Fusion Proteins Thereof
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
EP4330381A1 (de) 2021-04-27 2024-03-06 Novartis AG System zur herstellung von viralen vektoren
JP2024522357A (ja) 2021-06-01 2024-06-18 トリウムビラ イミュノロジクス ユーエスエー，インク． クローディン１８．２ｔ細胞－抗原カプラーおよびその使用
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
KR20240053675A (ko) 2021-08-11 2024-04-24 악소 바이오파마슈티컬 인코포레이티드 sBCMA 변이체 및 이의 FC 융합 단백질을 이용한 IgA, IgM 및/또는 IgG의 생산 감소 방법
JP2024531364A (ja) 2021-08-20 2024-08-29 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品
EP4683948A1 (de) 2023-03-21 2026-01-28 Biograph 55, Inc. Multispezifische cd19/cd38-antikörper
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2025170844A1 (en) * 2024-02-05 2025-08-14 Board Of Regents, The University Of Texas System Chimeric polypeptides and methods of use
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CN1214050A (zh) 1996-03-14 1999-04-14 人体基因组科学有限公司 人肿瘤坏死因子δ和ε
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
HU230547B1 (hu) 1997-04-16 2016-11-28 Amgen Inc. Osteoprotegerin-kötő fehérjék és receptorok
WO1998055620A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
JP2002517977A (ja) 1997-06-06 2002-06-18 リジェネロン ファーマシューティカルズ，インコーポレイテッド Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
HUP0004611A3 (en) * 1997-09-12 2002-04-29 Apotech R & D Sa April- a novel protein with growth effects
HUP0004034A3 (en) * 1997-09-12 2002-08-28 Apotech R & D Sa Kay - a novel immune system protein
CA2301173C (en) 1997-09-12 2015-04-14 Biogen, Inc. Cysteine rich receptors-train
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
DE69921718T2 (de) * 1998-04-01 2005-12-22 Solvay Solexis, Inc., Wilmington Verträgliche Mischungen aus Polyvinylidenfluorid und aromatischem Polyimid
WO2000026244A2 (en) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
ATE437227T1 (de) † 1999-01-07 2009-08-15 Zymogenetics Inc Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
PL198934B1 (pl) * 1999-01-25 2008-08-29 Apoxis Sa Zastosowanie przeciwciała swoistego wobec rozpuszczalnego BAFF lub aktywnego fragmentu przeciwciała i zastosowanie rozpuszczalnego BAFF lub jego aktywnego fragmentu
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
WO2000050633A1 (en) 1999-02-24 2000-08-31 The General Hospital Corporation Method for cloning signal transduction intermediates
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
US6475987B1 (en) 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
EP1806143B1 (de) * 1999-08-17 2016-06-15 Biogen MA Inc. BAFF-Rezeptor (BCMA), ein immunregulatorischer Wirkstoff
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2001234953B2 (en) 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
ATE511857T1 (de) † 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
WO2001087979A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
KR20120053525A (ko) 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
CA2419661A1 (en) 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1456347A4 (de) 2001-11-16 2006-08-02 Human Genome Sciences Inc Immunspezifisch an blys bindende antikörper
US20080267965A1 (en) 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
US7083735B2 (en) 2003-09-03 2006-08-01 Laing David A High debris content strainer
FI3415531T3 (fi) 2011-05-27 2023-09-07 Glaxo Group Ltd Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
FR3005792B1 (fr) 2013-05-16 2017-12-29 Parknplug Procede de gestion dynamique et previsionnel du rechargement electrique de batteries

Also Published As

Publication number Publication date
PL211786B1 (pl) 2012-06-29
US20200095305A1 (en) 2020-03-26
HU1000128D0 (en) 2010-05-28
JP5379107B2 (ja) 2013-12-25
US7691804B2 (en) 2010-04-06
US20120214687A1 (en) 2012-08-23
TR200201063T2 (tr) 2002-10-21
US8828669B2 (en) 2014-09-09
CN1379815A (zh) 2002-11-13
CZ300364B6 (cs) 2009-04-29
HU230583B1 (hu) 2017-02-28
EP1806143A2 (de) 2007-07-11
JP4787439B2 (ja) 2011-10-05
DE60034579T3 (de) 2015-11-12
EP1210425B1 (de) 2007-04-25
HK1043608B (en) 2007-12-07
GEP20053685B (en) 2005-12-12
EP2314694A3 (de) 2013-12-11
NZ517782A (en) 2004-01-30
CA2383154A1 (en) 2001-02-22
WO2001012812A3 (en) 2001-09-07
SK288287B6 (sk) 2015-07-01
JP5904985B2 (ja) 2016-04-20
IL230961A (en) 2016-06-30
US20150139992A1 (en) 2015-05-21
EA004635B1 (ru) 2004-06-24
HUP0203084A2 (en) 2002-12-28
DK1210425T4 (en) 2015-08-10
US10494416B2 (en) 2019-12-03
NO20020789L (no) 2002-04-08
EP2314694A2 (de) 2011-04-27
US20020172674A1 (en) 2002-11-21
CN100447244C (zh) 2008-12-31
EA200200261A1 (ru) 2002-08-29
PL354661A1 (en) 2004-02-09
DK1210425T3 (da) 2007-09-17
WO2001012812A2 (en) 2001-02-22
US7083785B2 (en) 2006-08-01
DE60034579T2 (de) 2008-01-31
YU10602A (sh) 2005-06-10
EP1210425A2 (de) 2002-06-05
IL148089A0 (en) 2002-09-12
NO344346B1 (no) 2019-11-11
HK1043608A1 (en) 2002-09-20
IL148089A (en) 2015-03-31
KR20020084842A (ko) 2002-11-11
EP1806143B1 (de) 2016-06-15
BRPI0013391B1 (pt) 2018-09-11
DE60034579D1 (de) 2007-06-06
IL230961A0 (en) 2014-03-31
BRPI0013391B8 (pt) 2021-05-25
SK288603B6 (sk) 2018-10-01
US20020165156A1 (en) 2002-11-07
EE200200071A (et) 2003-04-15
IS6273A (is) 2002-02-15
SK2292002A3 (en) 2002-07-02
EE05673B1 (et) 2013-08-15
SK500172015A3 (de) 2002-07-02
KR20090016772A (ko) 2009-02-17
BG106519A (bg) 2003-04-30
AU6911200A (en) 2001-03-13
US20100040627A1 (en) 2010-02-18
IS2955B (is) 2016-12-15
PL207501B1 (pl) 2010-12-31
RS51157B (sr) 2010-10-31
HU227947B1 (en) 2012-06-28
NO20020789D0 (no) 2002-02-18
UA75049C2 (uk) 2006-03-15
US20180273605A1 (en) 2018-09-27
EP1806143A3 (de) 2007-07-18
HU227008B1 (en) 2010-04-28
JP2011116790A (ja) 2011-06-16
AU780240B2 (en) 2005-03-10
JP2011063600A (ja) 2011-03-31
MXPA02001665A (es) 2003-07-14
BR0013391A (pt) 2002-07-09
EP1210425B2 (de) 2015-06-17
NO331410B1 (no) 2011-12-19
KR100897082B1 (ko) 2009-05-14
CZ2002579A3 (cs) 2002-05-15
NO20111232A1 (no) 2011-09-12
US9650430B2 (en) 2017-05-16
CA2383154C (en) 2013-04-30
JP2003507364A (ja) 2003-02-25
JP2014037434A (ja) 2014-02-27

Similar Documents

Publication Publication Date Title
ATE360693T1 (de) Baff rezeptor (bcma), ein immunoregulatorisches mittel
DE60034586D1 (de) April rezeptor (bcma) und verwendungen davon
ATE416771T1 (de) N-ä4-(4-amino-2-ethyl-1h-imidazoä4,5-cüchinolin 1-yl)butylümethanesulfonamide, diese enthaltende pharmazeutische zusammensetzung und deren verwendung
EP1669688A4 (de) Fluidheizvorrichtung und diese verwendende reinigungsvorrichtung
DE60129841D1 (de) Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
ATE241612T1 (de) 2-(iminoethyl)-aminophenyl - derivate, deren herstellung, deren verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
FR2802455B1 (fr) Dispositif d'extracteur d'electrode
Hansen Laboratory directed research and development FY2002 report
SE0202245D0 (sv) Novel sequence information and methods for its use in diagnosis and therapy VI.2
FR2849941B1 (fr) Procede d'obtention de puissances entieres ou de series de puissances entieres, et dispositif faisant application
ES1044058Y (es) Marco expositor perfeccionado.
DK199900124U3 (da) Bærbar stol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1210425

Country of ref document: EP